GVR Report cover Dog Vaccine Market Size, Share & Trends Report

Dog Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type, By Disease Type, By Route Of Administration, By Duration Of Immunity, By Component, By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68040-156-3
  • Number of Pages: 115
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Dog Vaccine Market Size & Trends

The global dog vaccine market size was estimated at USD 1.6 million in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2030. The growth of this market can be attributed to the rising pet ownership and pet humanization that encourages treating pets as family members and providing them with utmost care and comfort. According to an article posted by My Golden Retriever Puppies in August 2023, dogs and cats are the most loved and popular pet animals in the world, and there are approximately 89.7 million pet dogs in the U.S.

U.S. dog vaccine market size and growth rate, 2023 - 2030

The global market is further expected to grow owing to the rising awareness about vaccination among the canine population. Several governmental and non-governmental organizations are increasing awareness and carrying out dog vaccination campaigns. For instance, according to an article published by the World Health Organization in September 2022, with the help of the government and some organizations, about 81.6% of dogs were vaccinated in Bangladesh by June 2022. The rising efforts of mass dog vaccination in several countries are expected to boost the demand for the product.

In addition, the rising pet ownership among millennials and their emphasis on preventive healthcare for dogs are expected to be major drivers for the market for dog vaccine. According to the National Pet Owners Survey conducted by the American Pet Products Association, Inc. 2023-2024, millennials owned the largest pet ownership share of 33%. Another article published by Women's Health (Hearst UK) in May 2023 suggested that a survey on dog owners showed that 63% of millennials were spending more on their dogs than themselves. This is expected to further add to the growth of this industry in the future.

The disruption in the supply chain globally and the fear of catching an infection had adversely affected this market during the COVID-19 pandemic. At the same time, the pandemic also led to an increased pet adoption rate and health consciousness among people, which is expected to foster the growth in the global market. According to Health For Animals, more than two million people in the UK adopted a pet during the COVID-19 pandemic.

Vaccine Type Insights

The market is segmented based on the vaccine type into modified/attenuated live, inactivated (killed), and others. The modified/attenuated live segment accounted for the largest revenue share of 52.4% in 2022. The attenuated live vaccine can protect against disease and infection and provide long-term immunity, driving their market. All canine adenovirus-2 and parvoviruses, such as canine adenovirus type 2 (CAV-2), are attenuated live vaccines. The CAV-2 vaccine helps in the protection of infectious hepatitis.

The other segment is expected to grow at the fastest CAGR of 8.1% over the forecast period. The innovation in the dog vaccine has led to the development of new and more effective canine vaccines, such as recombinant vaccines, which insert a pathogen gene into the virus in combination with other antigens. For instance, Recombitek is a recombinant vaccine developed by Boehringer Ingelheim International GmbH to protect against distemper, leptospirosis, and other diseases.

Disease Type Insights

Based on disease type, the market is segmented into canine infectious respiratory disease complex (CIRDC), canine distemper, canine rabies, canine leptospirosis, canine Lyme disease, infectious canine hepatitis, canine parvovirus/parvovirus disease, and other diseases. The CIRDC segment accounted for the largest revenue share of 27.3% in 2022. The existence of several causal agents for CIRDC has encouraged the development of new vaccines. For instance, in November 2019, Zoetis launched the first of its kind, Plus Bb Oral, in Europe to protect against one of the primary causal agents of CIRDC, Bordetella bronchiectasis. The vaccine is expected to provide a comfortable route of administration for one year.

The canine rabies segment is estimated to register the fastest CAGR of 6.9% over the forecast period from 2023-2030. This growth can be attributed to the prevalence of canine rabies, its zoonotic potential, and efforts by public and private players to create awareness and prevent rabies. For instance, in September 2021, jbfsociety.org launched an anti-rabies vaccination program for dogs in Northeast India intending to make society rabies-free until 2030. Such initiatives are likely to foster the demand for canine rabies vaccines over the forecast period.

Component Insights

Based on the components, the market is segmented into combined vaccines and mono vaccines. The combined vaccine segment held the largest revenue share of 65.5% in 2022 and is expected to grow at the fastest CAGR of 6.2% over the forecast period from 2023-2030.

Global dog vaccine market share and size, 2022

Administration of combined vaccines helps protect against more than one disease and reduce the requirement for several injections a dog needs for different diseases. This makes the vaccine procedures more convenient and less stressful which is expected to drive their demand in the dog vaccine industry. For instance, Nobivac Puppy DP by Merck & Co, Inc. is a combined vaccine to protect against canine distemper and canine parvovirus.

Route of Administration Insights

Based on the route of administration, the market is segmented into injectable, intranasal, and oral vaccines. The injectable segment held the largest revenue share of 76.1% in 2022. Injectable vaccines are the most popular among veterinarians and pet owners due to their ability to facilitate accurate dosage. In March 2021, MSD Animal Health (Merck & Co., Inc.) launched an injectable vaccine to protect against Bordetella bronchieseptica, Nobivac(r) Respira Bb. The single-dose administration of the vaccine can protect dogs against disease for seven months after the primary course and 12 months after the booster dose.

The oral vaccine segment is expected to grow at the fastest CAGR of 7.1% over the forecast period from 2023-2030. Oral vaccines are considered more convenient as the pet owners can administer them. In addition, oral vaccines are also easy to supply since they require less stringent cold chain storage. This is likely to encourage the development and increase the adoption rate for these vaccines. For instance, in September 2022, Merck Animal Health (Merck & Co., Inc.) launched the first oral vaccine for two canine respiratory pathogens, including parainfluenza virus and Bordetella bronchiseptica.

Duration of Immunity Insights

Based on the duration of immunity, the market is segmented into one year, three years, and other vaccines. The one-year segment held the largest revenue share of 51.2% in 2022. The vaccine offering one year of immunity can help protect against common diseases without the need for frequent booster shots. This provides a convenient option for dog owners and is likely to foster further growth in the market.

The other vaccine segment is expected to grow at the fastest CAGR of 7.0% over the forecast period from 2023-2030. Some canine vaccines can provide immunity for over three to seven years, and some may require booster shots. The longer duration of vaccines can provide additional benefits by reducing the need for frequent clinic visits. A study published in the National Library of Medicine in April 2020 suggests that the rabies vaccine can induce immunity for more than three years without frequent re-vaccination.

Regional Insights

North America accounted for the largest revenue share of 38.8% in 2022. The region has a presence of several key players in the dog vaccines market. In addition, the rising awareness regarding preventive healthcare for pets and increasing pet ownership rates are major growth drivers for this market. For instance, the combined efforts by Merck & Co., Inc., Petco Love, and NGO helped distribute one million free pet vaccines by October 2022.

Dog Vaccine Market Trends, by Region, 2023 - 2030

Asia Pacific is expected to grow at the fastest CAGR of 7.0% during the forecast period. The region has the presence of several emerging economies, such as India and China. The growing income levels, changing demographics, and improvement in the standard of living are expected to foster the growth of the market in this region. According to an article published by CNBC in October 2022, India is expected to experience the biggest hike of 4.6% in real wages, whereas 3.6% growth is expected in China. This rise in income levels is expected to encourage more spending on pets.

Key Companies & Market Share Insights

The key players in this market are engaged in strategies such as new product and trial launches, mergers & acquisitions, and partnerships and collaborations to increase their market shares. For instance, in June 2023, Boehringer Ingelheim International GmbH collaborated with MebGenesis Inc. to develop monoclonal antibodies in canines. Similarly, in June 2022, Zoetis Services LLC acquired Basepaws Inc., which is likely to help improve its market offerings in precision animal health. Such developments are likely to foster growth in this market.

Key Dog Vaccine Companies:

  • Bioveta a.s
  • Hester Biosciences Limited
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac
  • Zendal Group
  • Elanco
  • Zoetis Services LLC.

Dog Vaccine Market Report Scope

Report Attribute


Market size value in 2023

USD 1.7 billion

Revenue forecast in 2030

USD 2.6 billion

Growth rate

CAGR of 6.0% from 2023 to 2030

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2030

Quantitative units

Revenue in USD million/billion, and CAGR from 2023 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Vaccine type, disease type, route of administration, duration of immunity, component, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Bioveta a.s; Hester Biosciences Limited; Boehringer Ingelheim International GmbH; Brilliant Bio Pharma; Heska Corporation; Merck & Co., Inc.; Virbac; Zendal Group; Elanco; Zoetis Services LLC.

Customization scope

Free report customization (equivalent up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Dog Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global dog vaccine market report based on vaccine type, disease type, route of administration, duration of immunity, component, and region:

  • Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)

    • Modified/ Attenuated Live

    • Inactivated (Killed)

    • Others

  • Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

    • Canine Distemper

    • Canine Infectious Respiratory Disease Complex (CIRDC)

    • Canine Parvovirosis/ Parvovirus Disease

    • Canine Leptospirosis

    • Canine Lyme Disease

    • Infectious Canine Hepatitis

    • Canine Rabies

    • Other Diseases

  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

    • Injectable

    • Intranasal

    • Oral

  • Duration of Immunity Outlook (Revenue, USD Million, 2018 - 2030)

    • 1-Year

    • 3-Year

    • Others

  • Component Outlook (Revenue, USD Million, 2018 - 2030)

    • Combined Vaccines

    • Mono Vaccines

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.